NO316987B1 - Fremgangsmate for fremstilling av 4,10-diacetoksy-2<alfa>-benzoyloksy-5<beta>,20-epoksy-1,7<beta>-dihydroksy-9-okso-tax-11-en-13<alfa>-YL (2R,3S)-3-benzoylamino-2-hydroksy-3-fenylpropionat-trihydrat og den oppnadde forbindelse - Google Patents
Fremgangsmate for fremstilling av 4,10-diacetoksy-2<alfa>-benzoyloksy-5<beta>,20-epoksy-1,7<beta>-dihydroksy-9-okso-tax-11-en-13<alfa>-YL (2R,3S)-3-benzoylamino-2-hydroksy-3-fenylpropionat-trihydrat og den oppnadde forbindelse Download PDFInfo
- Publication number
- NO316987B1 NO316987B1 NO19973247A NO973247A NO316987B1 NO 316987 B1 NO316987 B1 NO 316987B1 NO 19973247 A NO19973247 A NO 19973247A NO 973247 A NO973247 A NO 973247A NO 316987 B1 NO316987 B1 NO 316987B1
- Authority
- NO
- Norway
- Prior art keywords
- hydroxy
- tax
- oxo
- epoxy
- diacetoxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 14
- 150000001875 compounds Chemical class 0.000 title claims description 4
- RRGNLQYIUYOTQC-LQFAMLORSA-N (2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoic acid trihydrate Chemical compound O.O.O.C(C1=CC=CC=C1)(=O)N[C@H]([C@H](C(=O)O)O)C1=CC=CC=C1 RRGNLQYIUYOTQC-LQFAMLORSA-N 0.000 title claims description 3
- 238000002360 preparation method Methods 0.000 title claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- HYJVYOWKYPNSTK-UONOGXRCSA-N (2r,3s)-3-benzamido-2-hydroxy-3-phenylpropanoic acid Chemical compound N([C@H]([C@@H](O)C(O)=O)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 HYJVYOWKYPNSTK-UONOGXRCSA-N 0.000 claims description 13
- 150000004684 trihydrates Chemical class 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229930190007 Baccatin Natural products 0.000 claims 1
- 230000032050 esterification Effects 0.000 claims 1
- 238000005886 esterification reaction Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 description 11
- 229960001592 paclitaxel Drugs 0.000 description 11
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- -1 Taxol trihydrate Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- RDVJYGYJBUIIOE-ZOAFEQKISA-N (4s,5r)-3-benzoyl-2-(4-methoxyphenyl)-4-phenyl-1,3-oxazolidine-5-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1N(C(=O)C=2C=CC=CC=2)[C@@H](C=2C=CC=CC=2)[C@H](C(O)=O)O1 RDVJYGYJBUIIOE-ZOAFEQKISA-N 0.000 description 2
- OVMSOCFBDVBLFW-VHLOTGQHSA-N 5beta,20-epoxy-1,7beta,13alpha-trihydroxy-9-oxotax-11-ene-2alpha,4alpha,10beta-triyl 4,10-diacetate 2-benzoate Chemical compound O([C@@H]1[C@@]2(C[C@H](O)C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)O)C(=O)C1=CC=CC=C1 OVMSOCFBDVBLFW-VHLOTGQHSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- ZCENSCKYAOOUGL-CZUORRHYSA-N (2R,3S)-2-amino-2-hydroxy-4-oxo-3,4-diphenylbutanoic acid Chemical compound C(C1=CC=CC=C1)(=O)[C@H]([C@](C(=O)O)(O)N)C1=CC=CC=C1 ZCENSCKYAOOUGL-CZUORRHYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- YWLXLRUDGLRYDR-SKXCCXORSA-N 10-dab iii Chemical compound O([C@H]1C2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-SKXCCXORSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229930014667 baccatin III Natural products 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical group C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Epoxy Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9500816A FR2729666A1 (fr) | 1995-01-25 | 1995-01-25 | Procede de preparation du trihydrate du (2r, 3s)- benzoylamino-2-hydroxy-3-phenylpropionate de 4,10-diacetoxy- 2alpha-benzoyloxy-5beta,20-epoxy-1,7beta-dihydroxy-9-oxo- tax-11-en-13alpha-yle |
| PCT/FR1996/000104 WO1996022984A1 (fr) | 1995-01-25 | 1996-01-23 | PROCEDE DE PREPARATION DU TRIHYDRATE DU (2R,3S)-3-BENZOYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4,10-DIACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1,7β-DIHYDROXY-9-OXO-TAX-11-EN-13α-YLE |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO973247D0 NO973247D0 (no) | 1997-07-11 |
| NO973247L NO973247L (no) | 1997-07-11 |
| NO316987B1 true NO316987B1 (no) | 2004-07-19 |
Family
ID=9475464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19973247A NO316987B1 (no) | 1995-01-25 | 1997-07-11 | Fremgangsmate for fremstilling av 4,10-diacetoksy-2<alfa>-benzoyloksy-5<beta>,20-epoksy-1,7<beta>-dihydroksy-9-okso-tax-11-en-13<alfa>-YL (2R,3S)-3-benzoylamino-2-hydroksy-3-fenylpropionat-trihydrat og den oppnadde forbindelse |
Country Status (43)
| Country | Link |
|---|---|
| US (1) | US6002022A (cs) |
| EP (1) | EP0805806B1 (cs) |
| JP (1) | JP3782449B2 (cs) |
| KR (1) | KR100384773B1 (cs) |
| CN (1) | CN1067997C (cs) |
| AP (1) | AP750A (cs) |
| AT (1) | ATE187719T1 (cs) |
| AU (1) | AU707603B2 (cs) |
| BG (1) | BG62769B1 (cs) |
| BR (1) | BR9606853A (cs) |
| CO (1) | CO4700286A1 (cs) |
| CZ (1) | CZ287079B6 (cs) |
| DE (1) | DE69605651T2 (cs) |
| DK (1) | DK0805806T3 (cs) |
| DZ (1) | DZ1977A1 (cs) |
| EE (1) | EE03396B1 (cs) |
| ES (1) | ES2139332T3 (cs) |
| FI (1) | FI119245B (cs) |
| FR (1) | FR2729666A1 (cs) |
| GE (1) | GEP19991833B (cs) |
| GR (1) | GR3032110T3 (cs) |
| HU (1) | HU223352B1 (cs) |
| IL (1) | IL116903A (cs) |
| IN (1) | IN184427B (cs) |
| IS (1) | IS2033B (cs) |
| MA (1) | MA23782A1 (cs) |
| MY (1) | MY113230A (cs) |
| NO (1) | NO316987B1 (cs) |
| NZ (1) | NZ300958A (cs) |
| OA (1) | OA10438A (cs) |
| PE (1) | PE64896A1 (cs) |
| PL (1) | PL183773B1 (cs) |
| PT (1) | PT805806E (cs) |
| RO (1) | RO115728B1 (cs) |
| RU (1) | RU2154642C2 (cs) |
| SK (1) | SK281958B6 (cs) |
| TN (1) | TNSN96011A1 (cs) |
| TR (1) | TR199700676T1 (cs) |
| TW (1) | TW356469B (cs) |
| UA (1) | UA47420C2 (cs) |
| UY (1) | UY24149A1 (cs) |
| WO (1) | WO1996022984A1 (cs) |
| ZA (1) | ZA96523B (cs) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL203300B1 (pl) * | 2000-10-31 | 2009-09-30 | Akad Medyczna | Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego |
| US6891050B2 (en) * | 2001-08-10 | 2005-05-10 | Dabur India Limited | Process for the preparation of taxanes such as paclitaxel, docetaxel and structurally similar analogs |
| US6894456B2 (en) | 2001-11-07 | 2005-05-17 | Quallion Llc | Implantable medical power module |
| US6881852B2 (en) * | 2002-02-05 | 2005-04-19 | Dabur India Limited | Process of purification of paclitaxel and docetaxel |
| US7247738B2 (en) * | 2002-05-07 | 2007-07-24 | Dabur India Limited | Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl) ethoxycarbonyl]-5-oxazolidine carboxylic acids |
| US6900342B2 (en) * | 2002-05-10 | 2005-05-31 | Dabur India Limited | Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof |
| US6838569B2 (en) * | 2002-12-16 | 2005-01-04 | Dabur India Limited | Process for preparation of paclitaxel trihydrate and docetaxel trihydrate |
| WO2005061474A1 (en) * | 2003-12-12 | 2005-07-07 | Quiral Química Do Brasil | Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions |
| CN100420681C (zh) * | 2005-04-29 | 2008-09-24 | 上海奥锐特国际贸易有限公司 | 多烯紫杉醇三水物的制备方法 |
| WO2009137084A2 (en) * | 2008-05-07 | 2009-11-12 | Ivax Research, Llc | Processes for preparation of taxanes and intermediates thereof |
| US8633240B2 (en) * | 2012-06-01 | 2014-01-21 | The University Of Utah Research Foundation | Paclitaxel trihydrates and methods of making thereof |
| CN103833693B (zh) * | 2014-03-04 | 2016-02-24 | 悦康药业集团有限公司 | 一种紫杉醇化合物及含该紫杉醇化合物的药物组合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994021662A1 (en) * | 1993-03-15 | 1994-09-29 | Yale University | Diagnosis of human inflammatory bowel diseases and nucleic acid reagents therefor |
| FR2703049B1 (fr) * | 1993-03-22 | 1995-04-21 | Rhone Poulenc Rorer Sa | Procédé de purification des taxoïdes. |
| CA2163837C (en) * | 1994-12-13 | 1999-07-20 | Robert K. Perrone | Crystalline paclitaxel hydrates |
-
1995
- 1995-01-25 FR FR9500816A patent/FR2729666A1/fr active Granted
-
1996
- 1996-01-15 PE PE1996000035A patent/PE64896A1/es not_active Application Discontinuation
- 1996-01-17 UY UY24149A patent/UY24149A1/es not_active IP Right Cessation
- 1996-01-22 DZ DZ960018A patent/DZ1977A1/fr active
- 1996-01-23 RU RU97114134/04A patent/RU2154642C2/ru not_active IP Right Cessation
- 1996-01-23 CN CN96191612A patent/CN1067997C/zh not_active Expired - Fee Related
- 1996-01-23 RO RO97-01401A patent/RO115728B1/ro unknown
- 1996-01-23 CZ CZ19972362A patent/CZ287079B6/cs not_active IP Right Cessation
- 1996-01-23 ZA ZA96523A patent/ZA96523B/xx unknown
- 1996-01-23 ES ES96901832T patent/ES2139332T3/es not_active Expired - Lifetime
- 1996-01-23 GE GEAP19963849A patent/GEP19991833B/en unknown
- 1996-01-23 NZ NZ300958A patent/NZ300958A/en not_active IP Right Cessation
- 1996-01-23 AP APAP/P/1997/001035A patent/AP750A/en active
- 1996-01-23 AU AU46255/96A patent/AU707603B2/en not_active Ceased
- 1996-01-23 PL PL96321493A patent/PL183773B1/pl not_active IP Right Cessation
- 1996-01-23 DE DE69605651T patent/DE69605651T2/de not_active Expired - Lifetime
- 1996-01-23 HU HU9801437A patent/HU223352B1/hu not_active IP Right Cessation
- 1996-01-23 MA MA24137A patent/MA23782A1/fr unknown
- 1996-01-23 UA UA97063414A patent/UA47420C2/uk unknown
- 1996-01-23 EE EE9700157A patent/EE03396B1/xx not_active IP Right Cessation
- 1996-01-23 BR BR9606853A patent/BR9606853A/pt not_active IP Right Cessation
- 1996-01-23 JP JP52266996A patent/JP3782449B2/ja not_active Expired - Lifetime
- 1996-01-23 TR TR97/00676T patent/TR199700676T1/xx unknown
- 1996-01-23 US US08/875,625 patent/US6002022A/en not_active Expired - Lifetime
- 1996-01-23 KR KR1019970705017A patent/KR100384773B1/ko not_active Expired - Fee Related
- 1996-01-23 AT AT96901832T patent/ATE187719T1/de active
- 1996-01-23 EP EP96901832A patent/EP0805806B1/fr not_active Expired - Lifetime
- 1996-01-23 SK SK1008-97A patent/SK281958B6/sk not_active IP Right Cessation
- 1996-01-23 TW TW085100768A patent/TW356469B/zh not_active IP Right Cessation
- 1996-01-23 PT PT96901832T patent/PT805806E/pt unknown
- 1996-01-23 DK DK96901832T patent/DK0805806T3/da active
- 1996-01-23 WO PCT/FR1996/000104 patent/WO1996022984A1/fr active IP Right Grant
- 1996-01-24 CO CO96002860A patent/CO4700286A1/es unknown
- 1996-01-24 TN TNTNSN96011A patent/TNSN96011A1/fr unknown
- 1996-01-24 IN IN152DE1996 patent/IN184427B/en unknown
- 1996-01-25 IL IL11690396A patent/IL116903A/xx not_active IP Right Cessation
- 1996-01-25 MY MYPI96000282A patent/MY113230A/en unknown
-
1997
- 1997-07-11 NO NO19973247A patent/NO316987B1/no not_active IP Right Cessation
- 1997-07-22 IS IS4529A patent/IS2033B/is unknown
- 1997-07-24 OA OA70055A patent/OA10438A/fr unknown
- 1997-07-24 FI FI973105A patent/FI119245B/fi not_active IP Right Cessation
- 1997-07-25 BG BG101794A patent/BG62769B1/bg unknown
-
1999
- 1999-12-16 GR GR990402251T patent/GR3032110T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4739055A (en) | Anhydrous, stable, crystalline δ-form of prazosin hydrochloride | |
| NO316987B1 (no) | Fremgangsmate for fremstilling av 4,10-diacetoksy-2<alfa>-benzoyloksy-5<beta>,20-epoksy-1,7<beta>-dihydroksy-9-okso-tax-11-en-13<alfa>-YL (2R,3S)-3-benzoylamino-2-hydroksy-3-fenylpropionat-trihydrat og den oppnadde forbindelse | |
| KR20100103614A (ko) | 디메톡시 도세탁셀의 결정질형과 이의 제조 방법 | |
| KR100403256B1 (ko) | 결정성n-아세틸뉴라민산유도체및그제조방법 | |
| ZA200209873B (en) | Crystal modification. | |
| AU2001265377A1 (en) | Crystal modification of fexofenadine | |
| WO2018067805A1 (en) | Solid state forms of sotagliflozin | |
| MXPA97005460A (en) | Procedure for the preparation of trihydrate (2r, 3s) -3-benzoylamino-2-hydroxy-3-phenylpropionate de4, 10-diacetoxy-2alfa-benzoiloxi-5beta; 20-epoxy-1, 7beta-dihidroxi-9-oxo-tax -11-en-13alfa- | |
| JP2008056574A (ja) | 結晶アスコピロンｐの製造法 | |
| EP2080763A1 (en) | Crystalline form I of ortataxel | |
| KR100429330B1 (ko) | 4,10β-디아세톡시-2α-벤조일옥시-5β,20-에폭시-1-하이드록시-9-옥소-19-노르-사이클로프로파[지]택스-11-엔-13α-일(2알,3에스)-3급-부톡시카보닐아미노-2-하이드록시-3-페닐프로피오네이트디하이드레이트및이의제조방법 | |
| AU2022230764A1 (en) | Solid forms of a 4h-pyran-4-one structured cyp11a1 inhibitor | |
| CN119707897A (zh) | 含笑内酯衍生物的制备方法 | |
| EP0845462B1 (en) | Process for the production of the form I of the terazosin monohydrochloride anhydrous | |
| KR100491479B1 (ko) | 제미플록사신 메실레이트의 향상된 건조 및 흡습 방법 | |
| HK1131781A (en) | Crystalline form i of ortataxel | |
| HK1141289A (en) | Stable anhydrous crystalline docetaxel and method for the preparation thereof | |
| HK1014187B (en) | Crystalline n-acetyl neuraminic acid derivatives and processes for their preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |